Market research
PBN.F Alterity Therapeutics Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.04
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000043945
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.04
About
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PBN.F discussion.
5 years, 5 months ago
Alterity Therapeutics Limited is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 48.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 673.5.
Alterity Therapeutics Limited's total revenue sank by 0.0% to $928K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 182.8% to $-4M since the same quarter in the previous year.
Based on the above factors, Alterity Therapeutics Limited gets an overall score of 1/5.